Development of an experimental model of tumor growth under hypothyroidism

Автор: Kit O.I., Frantsiyants E.M., Bandovkina V.A., Kaplieva I.V., Pogorelova Y.A., Trepitaki L.K., Neskubina I.V., Shikhlyarova A.I., Cheryarina N.D., Kachesova P.S., Nemashkalova L.A., Surikova E.I., Goroshinskaya I.A., Zhukova G.V., Volkova V.L., Chertova N.A., Еngibaryan M.A., Arakelova A.Y., Salatova A.M.

Журнал: Cardiometry @cardiometry

Рубрика: Original research

Статья в выпуске: 21, 2022 года.

Бесплатный доступ

Aim. Our aim has been to develop an experimental model of the tumor growth against the background of hypothyroidism in rats of both genders in order to study possible influence made by hypothyroidism on progression of malignant tumors of various histological types. Materials and methods. In our studies we have used 100 outbred albino rats of both genders, with an individual body mass of 150-180 g. The female rats (n=30) and the male rats (n=30) have received Mercazolil at a day dosage of 2,5 mg/100g of the body weight for 30 days. After hypothyroidism in the treated rodents had been confirmed, one group of them (15 females and 15 males) were subcutaneously inoculated with the Guerin's carcinoma cells, and another group (covering other 15 females and other 15 males) has been undergone to transplantation of the Sarcoma 45 cells. The reference group has included the rats of both genders with subcutaneously inoculated the Guerin's carcinoma cells (n=10 females and n=10 males) and Sarcoma 45 cells (n=10 females and n=10 males), but without reproduction of the hypothyroidism model. Upon expiration of one month, within the 3 day period, we have estimated with a radioisotope analysis (RIA) standard assay kits (Immunotech, Czekh Republic) the levels of the thyroid hormones in blood of the tested animals as follows: Triiodothyronine (T3) (pM/L), total Thyroxine (T4) (pM/L) and Thyroid-Stimulating Hormon (TSH) (μU/mL). The obtained data have been processed with Statistica 10.0. Results. Upon the treatment with Mercazolil, we have found in the females a decrease by a factor of 7,3 in the total level of Thyroxine and an increase by a factor 1,6 in the TSH level (p function show_abstract() { $('#abstract1').hide(); $('#abstract2').show(); $('#abstract_expand').hide(); }

Еще

Hypothyroidism, experimental model, rats, guerin's carcinoma, thyroxine, triiodothyronine, thyroid-stimulating hormon

Короткий адрес: https://sciup.org/148324178

IDR: 148324178

Список литературы Development of an experimental model of tumor growth under hypothyroidism

  • Vanderpump MPJ. The epidemiology of thyroid disease. Br Med Bull. 2011; 99: 39–51. DOI: 10.1093/bmb/ldr030.
  • Clayton JA, Collins FS. NIH to balance sex in cell and animals studies. Nature. 2014; 509: 282–283. DOI: 10.1038/509282a.
  • Bianco AC, et al. American thyroid association guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid. 2014; 24: 88–168. DOI: 10.1089/thy.2013.0109.
  • Rakov H, et al. Sex-specific phenotypes of hyperthyroidism and hypothyroidism in mice. Biology of sex differences. 2016; 7(1): 36. DOI:10.1186/s13293-016-0089-3.
  • Krashin E, et al. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol. 2019; 10: 59. DOI: 10.3389 / fendo.2019.00059.
  • Tran TV, et al. Thyroid dysfunction and cancer incidence: a systematic review and meta analysis. Endocr Relat Cancer. 2020; 27(4): 245–259. DOI: 10.1530 / ERC-19-0417.
  • Yuan S, et al. Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A two sample Mendelian randomization study. Int J Cancer. 2020; 147(7): 1895–1903. DOI: 10.1002/ijc.32988.
  • Weng CH, et al. Breast cancer risk in postmenopausal women with medical history of thyroid disorder in the women’s health initiative. Thyroid. 2020; 30(4): 519–530. DOI: 10.1089 / th.2019.0426.
  • Yang H, et al. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Med. 2020; 18(1): 225. DOI:10.1186/s12916-020-01690-y.
  • Sidorenko YuS, et al. Method for obtaining experimental malignant lung tumors. Patent for invention RU 2375758 C1, 10.12.2009. Application No. 2008133091/14 dated 11.08.2008. [in Russian]
  • Sidorenko YuS, Frantsiyants EM, Tkalya LD. A method for reproducing a malignant process in an experiment. Patent for invention RU 2388064 C1, 27.04.2010. Application No. 2008133088/14 dated 11.08.2008. [in Russian]
  • Kit OI, et al. A method for the prevention of metastatic lung damage in the experiment. Patent for invention RU 2546034 C1, 04/10/2015. Application No. 2013155850/15 dated 12/16/2013. [in Russian]
  • Sidorenko YuS, Kartashov SZ, Frantsiyants EM. Method for the treatment of lung cancer. Patent for invention RU 2123342 C1, 12/20/1998. Application No. 95115286/14 dated 29.08.1995. [in Russian]
  • Zhukova GV, Shikhlyarova AI, Loginova LN, Protasova TP. Effects of combined exposure to low-intensity electromagnetic radiation of the millimeter range and complexes of essential amino acids in senile tumor-bearing rats. South Russian Journal of Cancer. 2020;1(4):38-46. DOI:10.37748/2687-0533-2020-1-4-5.
  • Kit OI, et al. A method for chronic pain modification of malignant B16 melanoma growth in mice. Patent for invention RU 2650587 C1, 04/16/2018. Application No. 2017114818 dated 04/26/2017. [in Russian]
  • Kit OI, et al. A method of chronic pain stimulation of malignant growth in the lungs of rats. Patent for invention RU 2676641 C1, 01/09/2019. Application No. 2018112353 dated 04/05/2018. [in Russian]
  • Kit OI, et al. A method for the abolition of genetically determined inhibition of the growth of a malignant tumor in the experiment. Patent for invention RU 2718671 C1, 04/13/2020. Application No. 2019124739 dated 08/01/2019. [in Russian]
Еще
Статья научная